NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 02:59PM ET
15.76
Dollar change
+0.26
Percentage change
1.68
%
IndexRUT P/E- EPS (ttm)-3.03 Insider Own14.97% Shs Outstand60.28M Perf Week-1.62%
Market Cap951.17M Forward P/E- EPS next Y-3.30 Insider Trans0.00% Shs Float51.32M Perf Month-4.89%
Enterprise Value542.17M PEG- EPS next Q-0.75 Inst Own99.30% Short Float24.54% Perf Quarter1.74%
Income-160.22M P/S- EPS this Y2.86% Inst Trans2.88% Short Ratio19.66 Perf Half Y-30.08%
Sales0.00M P/B2.91 EPS next Y-6.74% ROA-30.31% Short Interest12.59M Perf YTD-32.30%
Book/sh5.42 P/C1.68 EPS next 5Y-1.28% ROE-50.47% 52W High40.26 -60.85% Perf Year-35.80%
Cash/sh9.36 P/FCF- EPS past 3/5Y49.72% 44.65% ROIC-33.20% 52W Low10.91 44.45% Perf 3Y15.56%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility8.43% 7.99% Perf 5Y-93.16%
Dividend TTM- EV/Sales- EPS Y/Y TTM94.51% Oper. Margin- ATR (14)1.20 Perf 10Y-
Dividend Ex-Date- Quick Ratio8.06 Sales Y/Y TTM-100.00% Profit Margin- RSI (14)50.55 Recom1.23
Dividend Gr. 3/5Y- - Current Ratio8.06 EPS Q/Q17.20% SMA20-2.57% Beta2.82 Target Price53.90
Payout- Debt/Eq0.00 Sales Q/Q- SMA502.80% Rel Volume0.79 Prev Close15.50
Employees65 LT Debt/Eq0.00 EarningsMay 08 AMC SMA200-28.51% Avg Volume640.36K Price15.76
IPOApr 07, 2016 Option/ShortYes / Yes EPS/Sales Surpr.28.66% - Trades Volume506,667 Change1.68%
Date Action Analyst Rating Change Price Target Change
Apr-08-25Initiated Leerink Partners Outperform $45
Mar-18-25Initiated Wolfe Research Outperform $27
Sep-04-24Initiated Wedbush Outperform $45
Jul-16-24Initiated Evercore ISI Outperform
May-02-24Initiated Robert W. Baird Outperform $50
Mar-01-24Upgrade Wells Fargo Equal Weight → Overweight $12 → $35
Dec-20-23Initiated BTIG Research Buy $32
Dec-11-23Initiated Jefferies Buy $31
Dec-11-23Initiated Guggenheim Buy $44
May-04-20Initiated Piper Sandler Overweight $12
Jul-03-25 04:05PM
Jun-17-25 07:30AM
Jun-16-25 04:05PM
Jun-06-25 04:05PM
May-30-25 09:55AM
08:30AM Loading…
May-28-25 08:30AM
May-13-25 09:55AM
May-08-25 04:05PM
May-05-25 08:00AM
May-02-25 04:05PM
Apr-04-25 04:05PM
Mar-27-25 04:05PM
Mar-07-25 04:40PM
Feb-27-25 04:05PM
Feb-25-25 08:00AM
08:00AM Loading…
Feb-19-25 08:00AM
Feb-07-25 05:13PM
Jan-13-25 08:00AM
Jan-03-25 05:20PM
Dec-18-24 08:00AM
Dec-02-24 05:03PM
08:00AM
Nov-25-24 05:11PM
Nov-18-24 09:18PM
04:14PM
Nov-12-24 07:30AM
Nov-11-24 04:05PM
Nov-07-24 04:05PM
Nov-01-24 04:44PM
Oct-30-24 04:05PM
08:00AM Loading…
Oct-14-24 08:00AM
Oct-04-24 05:00PM
Oct-01-24 08:00AM
Sep-10-24 04:47PM
Aug-07-24 11:53PM
04:05PM
Jul-18-24 08:00AM
Jun-18-24 07:30AM
Jun-03-24 05:23PM
May-29-24 08:30AM
May-15-24 07:30AM
May-09-24 10:54PM
04:02PM
May-03-24 05:00PM
Apr-01-24 05:00PM
Mar-18-24 08:00AM
Mar-04-24 08:50AM
Mar-01-24 05:25PM
Feb-29-24 04:05PM
Feb-26-24 07:30AM
Feb-08-24 07:30AM
Feb-06-24 09:55AM
Feb-05-24 07:30AM
Feb-02-24 05:30PM
Dec-22-23 05:00PM
Dec-08-23 07:19AM
Dec-07-23 06:20PM
Nov-28-23 08:00AM
Nov-27-23 08:30AM
Nov-22-23 05:00PM
Nov-09-23 06:26PM
04:05PM
Nov-03-23 05:00PM
Oct-30-23 08:00PM
Oct-02-23 06:02PM
Sep-14-23 05:03PM
Sep-07-23 08:40AM
Sep-05-23 07:00AM
Aug-11-23 07:07AM
07:00AM
Jul-27-23 07:00AM
Jun-23-23 04:30PM
10:31AM
Jun-22-23 10:59AM
08:17AM
May-13-23 08:03AM
May-11-23 08:15AM
07:10AM
07:01AM
Apr-13-23 09:44AM
Apr-12-23 07:00AM
Mar-17-23 05:30PM
Mar-02-23 10:15AM
07:01AM
Feb-12-23 07:40AM
Jan-06-23 07:01AM
Jan-02-23 07:29AM
Dec-14-22 12:00PM
Dec-02-22 04:05PM
Nov-30-22 10:38AM
07:01AM
Nov-15-22 04:25PM
Nov-03-22 08:35AM
07:01AM
Oct-21-22 12:27PM
12:06PM
Oct-19-22 04:05PM
Oct-17-22 11:57AM
Oct-04-22 11:05AM
07:01AM
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Albers Jeffrey W.DirectorNov 06 '24Sale36.766,700246,31327,360Nov 08 04:53 PM
Albers Jeffrey W.DirectorOct 25 '24Sale36.4330010,92934,060Oct 28 04:41 PM
SESSIONS, LLCDirectorOct 25 '24Proposed Sale33.707,000235,900Oct 25 04:28 PM
Burrows Scott LChief Financial OfficerSep 03 '24Sale28.1718,531522,074116,422Sep 05 04:04 PM